Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3389 COMPOSE: Phase III trial of 177Lu-edotreotide versus standard of care in well-differentiated (WD) aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Therapeutic algorithm for well-differentiated (WD) high-grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors (G2 + G3 GEP-NETs) is not well established. Current ‘best standard of care’ include CAPTEM, FOLFOX and everolimus. Peptide Receptor Radionuclide Therapy (PRRT) could be useful in high grade NETs, however there is a lack of prospective evidence. 177Lu-edotreotide is an innovative radiolabeled somatostatin analogue with a favourable safety profile and efficacy. The ongoing Phase III trial COMPETE in G1 and G2 GEP-NETs is exploring the efficacy and safety of 177Lu-edotreotide, in comparison to everolimus.

Conference:

Presenting Author:

Authors: Hernando J, Halfdarnarson T, Halperin D, Reidy-Lagunes D, Kong G,

Keywords: neuroendocrine, NET, 177Lu-edotreotide, PRRT,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs

Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Reidy-Lagunes D

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Mirakhur B, Massien C,

Keywords: Lung NETs, lanreotide,